Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab

References

• Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564–572
   PubMedGoogle Scholar
• Muñoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury eye evaluation study. Arch Ophthalmol 2000;118:819–825
   PubMed Web of Science ®Google Scholar
• Coleman AL, Yu F, Ensrud KE, et al. The impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the study of osteoporotic fractures. Am J Ophthalmol 2010;150:683–691
   PubMed Web of Science ®Google Scholar
• Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–1436
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol 1991;109:1220–1231
   PubMed Web of Science ®Google Scholar
• Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999;117:1329–1345
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541–560
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
   PubMed Web of Science ®Google Scholar
• Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration: two-year results. Ophthalmol 2012;119:1388–1398
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier, JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab verses verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmol 2012;119:2537–2548
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Compliment factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419–421
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter R, Abel KJ, et al. Compliment factor H polymorphism and age-related macular degeneration. Science 2005;308:421–424
   PubMed Web of Science ®Google Scholar
• Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, et al. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41:355–367
   PubMed Web of Science ®Google Scholar
• Ufret-Vincenty RL, Aredo B, Liu X, et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. IOVS 2010;51:5878–5887
   PubMed Web of Science ®Google Scholar
• Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389–407
   PubMed Web of Science ®Google Scholar
• Xu YT, Want Y, Chen P, et al. Age-related maculopathy susceptibility 2 participates in the phagocytosis functions of the retinal pigment epithelium. Int J Ophthalmol 2012;5:125–132
   PubMed Web of Science ®Google Scholar
• Miller JW. Age-related macular degeneration revisited – Piecing the puzzle: the LXIX Edward Jackson Memorial Lecture. Am J Ophthalmol 2013;155:1–35
   PubMed Web of Science ®Google Scholar
• Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005;14:3227–3236
   PubMed Web of Science ®Google Scholar
• Yang Z, Camp NK, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006;314:992–993
   PubMed Web of Science ®Google Scholar
• DeWan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006;314:989–992
   PubMed Web of Science ®Google Scholar
• Schmidt S, Hauser MA, Scott WK, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 2006;78:852–864
   PubMed Web of Science ®Google Scholar
• DeAngelis MM, Silveira AC, Carr EA, et al. Genetics of age-related macular degeneration: current concepts, future directions. Semin Ophthalmol 2001;26:77–93
   Google Scholar
• Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-realted macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929–1934
   PubMed Web of Science ®Google Scholar
• Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDRL, and LRP6. Invest Ophthalmol Vis Sci 2006;47:329–355
   PubMed Web of Science ®Google Scholar
• Janik-Papis K, Zaras M, Krzyzanowska A, et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a polish population. Exp Mol Pathol 2009;87:234–238
   PubMed Web of Science ®Google Scholar
• Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89:344–349
   PubMed Web of Science ®Google Scholar
• Tian J, Qin X, Fang K, et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics 2012;13:779–787
   PubMedGoogle Scholar
• Imai D, Mori K, Horie-Inoue K, et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Inform 2010;3:53–59
   PubMedGoogle Scholar
• Brantley MA, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmol 2007;114:2168–2173
   PubMed Web of Science ®Google Scholar
• Orlin A, Hadley D, Chang W, et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012;32:4–9
   PubMed Web of Science ®Google Scholar
• Nakata I, Yamashiro K, Nakanishi H, et al. VEGF gene polymorphisms and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 2011;55:435–443
   PubMedGoogle Scholar
• Boltz A, Ruib M, Jonas JB, et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patient with wet age-related macular degeneration. Ophthalmol 2012;119:1615–1620
   PubMedGoogle Scholar
• Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic associations with response to intravitreal ranibizumab in patients with neovascular AMD. IOVS 2001;52:4694–4702
   Google Scholar
• Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93:610–613
   PubMed Web of Science ®Google Scholar
• Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmol 2012;119:2304–2311
   PubMed Web of Science ®Google Scholar
• Teper S, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Molecular Vision 2010;16:2598–2604
   PubMedGoogle Scholar
• Yamashiro K, Tomita K, Tsujikawa A, et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154:125–136
   PubMed Web of Science ®Google Scholar
• McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96:208–212
   PubMed Web of Science ®Google Scholar
• Ye X, Wang Y, Cahill H, et al. Norrin, frizzled-4 and Lrp5 signling in endothelial cells controls a genetic program for retinal vascularization. Cell 2009;139:285–298
   PubMed Web of Science ®Google Scholar